医药分化！稀缺龙头荟萃，港股通医疗ETF（159137）低位四连涨！机构提示港股“春节行情”

Core Viewpoint - The Hong Kong pharmaceutical market shows a mixed performance, with innovative drugs experiencing a significant pullback while the healthcare theme sector continues to rise, particularly the Hong Kong Stock Connect Healthcare ETF, which has achieved four consecutive gains [1][7]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) slightly declined by 0.19%, ending a three-day upward trend [1][7]. - The Hong Kong Stock Connect Healthcare ETF (159137) has risen for four consecutive days and has surpassed the 20-day moving average [1][7]. - The performance of constituent stocks in the Hong Kong Stock Connect Healthcare ETF is mixed, with "invisible orthodontics leader" Angelalign rising by 8% to reach a new high in over a year [9]. Group 2: Key Stocks and Trends - Notable stocks include WuXi Biologics, which increased by 3.45%, and AI healthcare leader JD Health, along with brain-computer interface concept stock BrainCo, both rising over 1% [9][10]. - Recent trends indicate a significant recovery in the Hong Kong pharmaceutical sector, suggesting a favorable cost-performance ratio for investments [10]. - Analysts from Southwest Securities and Open Source Securities recommend focusing on low-priced innovative drugs, brain-computer interfaces, and AI healthcare [10]. Group 3: Investment Opportunities - The Hong Kong Stock Connect Healthcare ETF (159137) includes many unique stocks not available in the A-share market, with 41 out of 50 constituent stocks being exclusive to Hong Kong [10]. - The ETF encompasses various hot concepts such as AI healthcare and brain-computer interfaces, providing a high-efficiency investment vehicle for core pharmaceutical assets [11]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) focuses entirely on innovative drug research and development companies, with the top ten weighted stocks accounting for over 73% of the ETF [11].